End-of-day quote
Shanghai S.E.
06:00:00 2024-05-15 pm EDT
|
5-day change
|
1st Jan Change
|
23.72
CNY
|
+0.13%
|
|
-2.55%
|
-5.23%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
65,086
|
125,791
|
113,862
|
86,922
|
61,592
|
57,192
|
-
|
-
|
Enterprise Value (EV)
1 |
77,050
|
139,217
|
127,150
|
100,183
|
80,958
|
72,656
|
74,915
|
71,809
|
P/E ratio
|
20.5
x
|
37.8
x
|
26.5
x
|
24.6
x
|
28.1
x
|
20
x
|
15.2
x
|
13.7
x
|
Yield
|
1.47%
|
0.8%
|
1.14%
|
1.19%
|
1.08%
|
1.58%
|
2.03%
|
2.55%
|
Capitalization / Revenue
|
2.28
x
|
4.15
x
|
2.92
x
|
1.98
x
|
1.49
x
|
1.29
x
|
1.13
x
|
1.07
x
|
EV / Revenue
|
2.7
x
|
4.59
x
|
3.26
x
|
2.28
x
|
1.96
x
|
1.64
x
|
1.48
x
|
1.34
x
|
EV / EBITDA
|
13.1
x
|
22.2
x
|
15.7
x
|
14.5
x
|
13.1
x
|
10.4
x
|
9.6
x
|
9.72
x
|
EV / FCF
|
-109
x
|
-75
x
|
-137
x
|
-64.1
x
|
-42.3
x
|
15.6
x
|
48.7
x
|
43.2
x
|
FCF Yield
|
-0.92%
|
-1.33%
|
-0.73%
|
-1.56%
|
-2.36%
|
6.39%
|
2.05%
|
2.31%
|
Price to Book
|
2.14
x
|
3.74
x
|
3.21
x
|
2.11
x
|
1.46
x
|
1.31
x
|
1.2
x
|
1.15
x
|
Nbr of stocks (in thousands)
|
2,562,899
|
2,562,899
|
2,562,899
|
2,672,157
|
2,672,399
|
2,672,399
|
-
|
-
|
Reference price
2 |
26.60
|
53.99
|
48.94
|
35.24
|
25.03
|
23.72
|
23.72
|
23.72
|
Announcement Date
|
3/30/20
|
3/29/21
|
3/22/22
|
3/27/23
|
3/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
28,585
|
30,307
|
39,005
|
43,952
|
41,400
|
44,429
|
50,502
|
53,609
|
EBITDA
1 |
5,874
|
6,282
|
8,105
|
6,889
|
6,160
|
6,999
|
7,802
|
7,390
|
EBIT
1 |
4,494
|
4,721
|
6,314
|
4,657
|
3,308
|
3,649
|
4,648
|
4,763
|
Operating Margin
|
15.72%
|
15.58%
|
16.19%
|
10.59%
|
7.99%
|
8.21%
|
9.2%
|
8.88%
|
Earnings before Tax (EBT)
1 |
4,526
|
4,678
|
6,054
|
4,574
|
3,265
|
4,328
|
5,563
|
6,381
|
Net income
1 |
3,322
|
3,663
|
4,735
|
3,731
|
2,386
|
3,140
|
4,124
|
4,595
|
Net margin
|
11.62%
|
12.09%
|
12.14%
|
8.49%
|
5.76%
|
7.07%
|
8.17%
|
8.57%
|
EPS
2 |
1.300
|
1.430
|
1.850
|
1.430
|
0.8900
|
1.185
|
1.561
|
1.734
|
Free Cash Flow
1 |
-705.7
|
-1,857
|
-926.7
|
-1,564
|
-1,913
|
4,645
|
1,537
|
1,662
|
FCF margin
|
-2.47%
|
-6.13%
|
-2.38%
|
-3.56%
|
-4.62%
|
10.46%
|
3.04%
|
3.1%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
66.38%
|
19.7%
|
22.49%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
147.92%
|
37.27%
|
36.17%
|
Dividend per Share
2 |
0.3900
|
0.4300
|
0.5600
|
0.4200
|
0.2700
|
0.3750
|
0.4817
|
0.6039
|
Announcement Date
|
3/30/20
|
3/29/21
|
3/22/22
|
3/27/23
|
3/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
11,957
|
10,382
|
10,893
|
10,270
|
12,341
|
10,871
|
10,445
|
9,305
|
10,699
|
10,157
|
10,889
|
10,631
|
11,279
|
10,475
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
1,615
|
863.1
|
1,136
|
1,046
|
1,064
|
1,427
|
1,255
|
659.6
|
-34.69
|
1,021
|
363.7
|
867.5
|
456
|
706.2
|
-
|
Operating Margin
|
13.5%
|
8.31%
|
10.43%
|
10.18%
|
8.62%
|
13.13%
|
12.02%
|
7.09%
|
-0.32%
|
10.06%
|
3.34%
|
8.16%
|
4.04%
|
6.74%
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
0.4600
|
0.1800
|
0.4200
|
0.3500
|
0.4800
|
0.3700
|
0.3000
|
0.1900
|
0.0400
|
0.2300
|
0.3050
|
0.3900
|
0.3050
|
0.1800
|
0.0500
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/22/22
|
4/26/22
|
8/29/22
|
10/30/22
|
3/27/23
|
4/28/23
|
8/29/23
|
10/30/23
|
3/26/24
|
4/29/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
11,964
|
13,426
|
13,289
|
13,261
|
19,366
|
15,465
|
17,724
|
14,617
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
2.037
x
|
2.137
x
|
1.639
x
|
1.925
x
|
3.144
x
|
2.21
x
|
2.272
x
|
1.978
x
|
Free Cash Flow
1 |
-706
|
-1,857
|
-927
|
-1,564
|
-1,913
|
4,645
|
1,537
|
1,662
|
ROE (net income / shareholders' equity)
|
11.6%
|
10.8%
|
12.4%
|
9.04%
|
5.29%
|
6.41%
|
8.03%
|
8.83%
|
ROA (Net income/ Total Assets)
|
4.53%
|
4.58%
|
5.35%
|
3.73%
|
2.18%
|
2.6%
|
2.9%
|
3.3%
|
Assets
1 |
73,341
|
79,904
|
88,433
|
100,022
|
109,663
|
120,786
|
142,401
|
139,215
|
Book Value Per Share
2 |
12.40
|
14.40
|
15.30
|
16.70
|
17.10
|
18.20
|
19.80
|
20.60
|
Cash Flow per Share
2 |
1.260
|
1.010
|
1.540
|
1.580
|
1.280
|
2.700
|
1.760
|
2.000
|
Capex
1 |
3,928
|
4,437
|
4,875
|
5,782
|
5,328
|
5,632
|
3,919
|
4,577
|
Capex / Sales
|
13.74%
|
14.64%
|
12.5%
|
13.15%
|
12.87%
|
12.68%
|
7.76%
|
8.54%
|
Announcement Date
|
3/30/20
|
3/29/21
|
3/22/22
|
3/27/23
|
3/26/24
|
-
|
-
|
-
|
Last Close Price
23.72
CNY Average target price
28.61
CNY Spread / Average Target +20.60% Consensus |
1st Jan change
|
Capi.
|
---|
| -5.23% | 7.92B | | +32.36% | 694B | | +30.77% | 593B | | -1.60% | 371B | | +20.07% | 331B | | +6.04% | 290B | | +14.77% | 239B | | +9.13% | 209B | | -3.97% | 209B | | +9.27% | 169B |
Other Pharmaceuticals
|